CompletedPhase 4NCT01086878
Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
Studying Acquired neutropenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Harvard School of Public Health (HSPH)
- Principal Investigator
- Shahin Lockman, MDHarvard School of Public Health (HSPH)
- Intervention
- cotrimoxazole(drug)
- Enrollment
- 222 enrolled
- Eligibility
- All sexes
- Timeline
- 2009 – 2010
Study locations (2)
- Princess Marina Hospital, Gaborone, Gaborone, Botswana
- Scottish Livingstone Hospital, Molepolole, Kweneng District, Botswana
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID) · Fogarty International Center of the National Institute of Health · Harvard Initiative for Global Health · The American Society of Tropical Medicine and Hygiene
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01086878 on ClinicalTrials.govOther trials for Acquired neutropenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06056297A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsX4 Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT00967785A Phase I Study of Mozobil in the Treatment of Patients With WHIMSNational Institute of Allergy and Infectious Diseases (NIAID)